BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3215 related articles for article (PubMed ID: 28539557)

  • 1. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
    Jindal V; Arora E; Gupta S
    Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive CD8
    Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
    Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
    Shum T; Kruse RL; Rooney CM
    Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
    Ginefra P; Lorusso G; Vannini N
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
    Yoon DH; Osborn MJ; Tolar J; Kim CJ
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
    Zhou SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.
    Vanichapol T; Chutipongtanate S; Anurathapan U; Hongeng S
    Biomed Res Int; 2018; 2018():1812535. PubMed ID: 29682521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-T cell therapy in melanoma: A future success story?
    Simon B; Uslu U
    Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.
    Scarfò I; Maus MV
    J Immunother Cancer; 2017; 5():28. PubMed ID: 28331617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma.
    Chmielewski M; Hombach AA; Abken H
    Immunol Rev; 2014 Jan; 257(1):83-90. PubMed ID: 24329791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential and promise for clinical application of adoptive T cell therapy in cancer.
    Li Y; Zheng Y; Liu T; Liao C; Shen G; He Z
    J Transl Med; 2024 May; 22(1):413. PubMed ID: 38693513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors.
    Xin G; Schauder DM; Jing W; Jiang A; Joshi NS; Johnson B; Cui W
    Proc Natl Acad Sci U S A; 2017 Jan; 114(4):740-745. PubMed ID: 28069963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 161.